[go: up one dir, main page]

MX2023006766A - Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer. - Google Patents

Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.

Info

Publication number
MX2023006766A
MX2023006766A MX2023006766A MX2023006766A MX2023006766A MX 2023006766 A MX2023006766 A MX 2023006766A MX 2023006766 A MX2023006766 A MX 2023006766A MX 2023006766 A MX2023006766 A MX 2023006766A MX 2023006766 A MX2023006766 A MX 2023006766A
Authority
MX
Mexico
Prior art keywords
methods
shp2
shp2 inhibitor
treating cancer
inhibitor compositions
Prior art date
Application number
MX2023006766A
Other languages
English (en)
Inventor
Mallika Singh
Robert J Nichols
Mark A Goldsmith
Christopher Schulze
Jacqueline Smith
David E Wildes
Stephen Kelsey
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63684567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2023006766(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of MX2023006766A publication Critical patent/MX2023006766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones y métodos de tratamiento o prevención de enfermedades o trastornos con inhibidores de SHP2, solo y en combinación con otros agentes terapéuticos tales como inhibidores de la vía RAS (por ejemplo, inhibidores de MEK); métodos de establecimiento de planes de tratamiento adecuados para sujetos con base en la expresión de uno o más biomarcadores indicativos de la sensibilidad con respecto a los inhibidores del SHP2; y métodos de determinación de la sensibilidad respecto a un inhibidor de SHP2 con base en un estado de fosforilación de SHP2.
MX2023006766A 2017-09-07 2020-03-06 Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer. MX2023006766A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762555400P 2017-09-07 2017-09-07
US201762558255P 2017-09-13 2017-09-13
US201862653831P 2018-04-06 2018-04-06
US201862681001P 2018-06-05 2018-06-05

Publications (1)

Publication Number Publication Date
MX2023006766A true MX2023006766A (es) 2023-06-19

Family

ID=63684567

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002608A MX2020002608A (es) 2017-09-07 2018-09-06 Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cáncer.
MX2023006766A MX2023006766A (es) 2017-09-07 2020-03-06 Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020002608A MX2020002608A (es) 2017-09-07 2018-09-06 Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cáncer.

Country Status (14)

Country Link
US (3) US11596633B2 (es)
EP (1) EP3678703A1 (es)
JP (2) JP7356414B2 (es)
KR (1) KR20200051684A (es)
CN (1) CN111344017A (es)
AU (1) AU2018328273A1 (es)
BR (1) BR112020004246A2 (es)
CA (1) CA3074690A1 (es)
CO (1) CO2020002588A2 (es)
IL (1) IL272877A (es)
MX (2) MX2020002608A (es)
SG (1) SG11202001282UA (es)
TW (1) TWI852912B (es)
WO (1) WO2019051084A1 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
JP7044375B2 (ja) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
EP3687997A1 (en) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
EP3759111A1 (en) 2018-03-02 2021-01-06 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical compounds
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
TWI879728B (zh) 2018-03-21 2025-04-11 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
JP7265275B2 (ja) 2018-03-21 2023-04-26 スージョウ プーヘー バイオファーマ カンパニー リミテッド Ｓｈｐ２阻害剤およびその使用
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
SG11202100719YA (en) 2018-07-24 2021-02-25 Taiho Pharmaceutical Co Ltd Heterobicyclic compounds for inhibiting the activity of shp2
US11104675B2 (en) 2018-08-10 2021-08-31 Navire Pharma, Inc. PTPN11 inhibitors
CA3113233A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
AU2019359885B2 (en) 2018-10-17 2024-01-18 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
EP3924053A1 (en) * 2019-02-12 2021-12-22 Novartis AG Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
MX2021009563A (es) * 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y ribociclib.
EP3930845A1 (en) 2019-03-01 2022-01-05 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
AU2020232242A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN111647000B (zh) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
AU2020232026A1 (en) 2019-03-07 2021-09-02 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
KR102698608B1 (ko) 2019-04-02 2024-08-27 어레이 바이오파마 인크. 단백질 티로신 포스파타제 억제제
AU2020271838A1 (en) 2019-04-08 2021-08-19 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
WO2020223177A1 (en) * 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor
TW202112761A (zh) * 2019-06-14 2021-04-01 中國商北京盛諾基醫藥科技股份有限公司 Shp2磷酸酶變構抑制劑
CN111579796A (zh) * 2020-05-19 2020-08-25 南方科技大学 一种高通量集成化磷酸化蛋白组学检测方法
JP2022547358A (ja) * 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114450287A (zh) 2019-09-24 2022-05-06 传达治疗有限公司 Shp2磷酸酶抑制剂及其制备和使用方法
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
AU2020371295A1 (en) * 2019-10-22 2022-04-28 Lupin Limited Pharmaceutical combination of PRMT5 inhibitors
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
CR20220241A (es) 2019-11-04 2022-08-03 Revolution Medicines Inc Inhibidores de ras
CN114901366A (zh) 2019-11-04 2022-08-12 锐新医药公司 Ras抑制剂
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
KR102546592B1 (ko) 2019-12-11 2023-06-23 일라이 릴리 앤드 캄파니 KRas G12C 억제제
EP4076667A1 (en) 2019-12-20 2022-10-26 Erasca, Inc. Tricyclic pyridones and pyrimidones
CA3163703A1 (en) * 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
WO2021142144A1 (en) 2020-01-10 2021-07-15 Immuneering Corporation Mek inhibitors and therapeutic uses thereof
EP4110338A1 (en) 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
TW202144334A (zh) * 2020-04-03 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜芳類衍生物游離鹼的晶型
AU2021293228A1 (en) 2020-06-18 2023-02-09 Revolution Medicines, Inc. Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
MX2023003338A (es) 2020-09-23 2023-06-14 Erasca Inc Piridonas y pirimidonas tricíclicas.
US20240058352A1 (en) * 2020-12-11 2024-02-22 Erasca, Inc. Combination therapies for the treatment of cancer
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
EP4313307A1 (en) 2021-04-01 2024-02-07 Array Biopharma Inc. Crystalline form of a shp2 inhibitor
CA3217920A1 (en) 2021-05-05 2022-11-10 Andreas BUCKL Ras inhibitors for the treatment of cancer
CN118234731A (zh) 2021-05-05 2024-06-21 锐新医药公司 Ras抑制剂
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
JP2024516037A (ja) 2021-05-05 2024-04-11 フヤバイオ インターナショナル，エルエルシー Ｓｈｐ２阻害剤とｐｄ－１阻害剤とを含む併用療法
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
WO2022271966A1 (en) * 2021-06-24 2022-12-29 Erasca, Inc. Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer
TW202317124A (zh) * 2021-06-24 2023-05-01 美商艾瑞斯卡公司 Erk1/2及shp2抑制劑之組合療法
IL309086A (en) 2021-09-01 2024-02-01 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
TW202339748A (zh) * 2021-10-06 2023-10-16 美商納維爾製藥有限公司 使用經取代之嘧啶-4(3h)-酮之治療方法
AU2022359757A1 (en) * 2021-10-06 2024-05-02 Erasca, Inc. Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4444310A2 (en) * 2021-12-10 2024-10-16 Verastem, Inc. Combination therapy for treating abnormal cell growth
WO2023147538A2 (en) * 2022-01-31 2023-08-03 D2G Oncology, Inc. Biomarkers for predicting responsiveness to shp2 inhibitor therapy
JP2025509202A (ja) 2022-03-04 2025-04-11 イーライ リリー アンド カンパニー Ｋｒａｓ ｇ１２ｃ阻害剤及びｓｈｐ２阻害剤を含む治療方法
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
EP4504185A1 (en) * 2022-04-06 2025-02-12 HepaRegeniX GmbH Pharmaceutical composition for the treatment of colon and lung cancer
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
KR20250022133A (ko) 2022-06-10 2025-02-14 레볼루션 메디슨즈, 인크. 거대고리 ras 억제제
WO2024130444A1 (en) * 2022-12-23 2024-06-27 The Governing Council Of The University Of Toronto Use of dupd1 inhibitors in the treatment of inflammatory bowel disease and metabolic disorders
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2636882A (en) 1950-08-11 1953-04-28 Quaker Oats Co Preparation of 3-pyridols from 2-acylfurans
BE758503A (fr) 1969-11-07 1971-05-05 Shell Int Research Compositions pesticides
GB1459571A (en) 1974-09-12 1976-12-22 Pfizer Ltd Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
JPH0249775A (ja) 1988-05-19 1990-02-20 Nippon Soda Co Ltd ６員環又は７員環を有する複素環化合物及びその製造方法
JPH04112877A (ja) 1990-09-04 1992-04-14 Nippon Soda Co Ltd 新規シアノピラジン誘導体及びその製造方法
WO1993009664A1 (fr) 1991-11-12 1993-05-27 Nippon Soda Co., Ltd. Materiau de conversion de la longueur d'onde de la lumiere, a usage dans l'agriculture
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
ES2168237T3 (es) 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
IL148243A0 (en) 1999-08-27 2002-09-12 Sugen Inc Trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and pharmaceutical compositions containing the same
EP1448587B1 (en) 2001-10-01 2009-09-02 Mount Sinai School of Medicine Noonan syndrome gene
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
MXPA05002418A (es) 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Derivados de 1,4-pirazina sustituidos.
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2856684B1 (fr) 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
MY147449A (en) 2003-08-15 2012-12-14 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1678160A1 (en) 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
DE102004015954A1 (de) 2004-04-01 2005-11-10 Ina-Schaeffler Kg Umschlingungstrieb
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
EP3061834B1 (en) 2005-10-21 2020-01-08 The Regents of the University of California Shp-2 gene mutations in melanoma
WO2007117699A2 (en) 2006-04-07 2007-10-18 University Of South Florida Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
WO2007127375A2 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US20120142685A1 (en) 2007-04-06 2012-06-07 Markus Rolf Dobler Organic compounds
US20100190980A1 (en) 2007-06-21 2010-07-29 Taisho Pharmaceutical Co., Ltd Pyrazinamide compound
CA2695621A1 (en) 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
AU2010291835A1 (en) 2009-09-03 2012-04-19 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
CN103181918B (zh) * 2011-05-04 2014-10-29 厦门大学 脂肪酸类化合物在制备预防和治疗肝癌药物中的应用
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014085490A1 (en) 2012-11-29 2014-06-05 Chemocentryx, Inc. Cxcr7 antagonists
WO2014113584A1 (en) 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
AU2014214326B2 (en) 2013-02-07 2018-07-05 Prexton Therapeutics Sa Substituted quinoxaline derivatives and their use as positive allosteric modulators of mGluR4
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
SG10201707855YA (en) 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
EP2826586A1 (en) 2013-07-18 2015-01-21 Siemens Aktiengesellschaft A method and a system for machining an object
US9815813B2 (en) 2014-01-17 2017-11-14 Novartis Ag 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015164862A1 (en) 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
CN106659788A (zh) 2014-06-13 2017-05-10 基因泰克公司 治疗和预防癌症耐药性的方法
EP4289950A3 (en) 2015-01-09 2024-01-24 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
AU2016213972B2 (en) 2015-02-05 2020-07-09 Tyrnovo Ltd. Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
CN107787323B (zh) 2015-06-19 2020-09-01 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
US10426842B2 (en) * 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
EP3355930A4 (en) 2015-10-01 2019-03-06 Warp Drive Bio, Inc. METHOD AND REAGENTS FOR THE ANALYSIS OF PROTEIN-PROTEIN INTERFACES
WO2017079723A1 (en) 2015-11-07 2017-05-11 Board Of Regents, The University Of Texas System Targeting proteins for degradation
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
PT3464272T (pt) 2016-06-07 2022-03-11 Jacobio Pharmaceuticals Co Ltd Novos derivados heterocíclicos úteis como inibidores de shp2
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
CN110730678B (zh) 2017-01-10 2022-07-15 诺华股份有限公司 包含alk抑制剂和shp2抑制剂的药物组合
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
JP2020513036A (ja) 2017-04-05 2020-04-30 レボリューション メディシンズ インコーポレイテッドＲｅｖｏｌｕｔｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． 協同的結合に関与する化合物及びその使用
US20210285955A1 (en) 2017-04-05 2021-09-16 Revolution Medicines, Inc. Methods and reagents for analyzing protein-protein interfaces
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
WO2019051084A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER
MX2020003579A (es) 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
TW201927791A (zh) 2017-12-15 2019-07-16 美商銳新醫藥公司 作為變構shp2抑制劑的多環化合物
CA3096535A1 (en) 2018-04-10 2019-10-17 Revolution Medicines, Inc. Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
KR20210089716A (ko) 2018-11-07 2021-07-16 상하이 린진 바이오파마 씨오., 엘티디. 질소 함유 축합 헤테로고리 shp2억제제 화합물, 제조방법 및 용도
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
KR20210097144A (ko) 2018-11-30 2021-08-06 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 및 5-원 질소 헤테로사이클 유도체, 이의 제조 방법, 및 이의 의학적 용도
CA3142430A1 (en) 2019-06-07 2020-12-10 Revolution Medicines, Inc. Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor

Also Published As

Publication number Publication date
JP2020533315A (ja) 2020-11-19
EP3678703A1 (en) 2020-07-15
JP2023139151A (ja) 2023-10-03
US20200368238A1 (en) 2020-11-26
JP7356414B2 (ja) 2023-10-04
US11596633B2 (en) 2023-03-07
CO2020002588A2 (es) 2020-06-19
RU2020112303A (ru) 2021-10-07
US20240058341A1 (en) 2024-02-22
TWI852912B (zh) 2024-08-21
MX2020002608A (es) 2020-09-18
CA3074690A1 (en) 2019-03-14
BR112020004246A2 (pt) 2020-09-01
US20250090532A1 (en) 2025-03-20
SG11202001282UA (en) 2020-03-30
AU2018328273A1 (en) 2020-03-12
CN111344017A (zh) 2020-06-26
WO2019051084A1 (en) 2019-03-14
TW201918260A (zh) 2019-05-16
KR20200051684A (ko) 2020-05-13
IL272877A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
EA202190630A1 (ru) Способы комбинированной терапии
PH12022550098A1 (en) Parp1 inhibitors
EA201992220A1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
MX2020011684A (es) Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
MX387283B (es) Tratamiento del cancer con tg02.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
MX371152B (es) Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk).
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
MX371150B (es) NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
MX2021006831A (es) Inhibidores de alk5.
MX2017005285A (es) Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
ZA202108579B (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
MX2022003396A (es) Uso de inhibidores de dkk-1 para tratar el cancer.
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.